Frontlight ResearchEarly access
Pancreatic cancer trials in China
326 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Not yet taking people in ChinaA Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 80
- Run by
- Zhejiang University
See details and how to joinNCT07736612 - No phaseNot yet taking people in ChinaBaduanjin for Quality of Life in Pancreatic Cancer Chemotherapy
- Where
- Tianjin
- Age
- 18 years and over
- People
- 96
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07791550 - Phase 1Taking peopleA Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- Where
- Beijing, Chengdu, Hangzhou, Jinan, Nanchang, Tianjin
- Age
- 18 years to 75 years
- People
- 96
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT05262491 - Phase 1/2Taking peopleStudy of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
- Where
- Beijing, Changsha, Hangzhou, Harbin, Nanjing, Shanghai, Taiyuan, Wuhan, Zhengzhou
- Age
- 18 years and over
- People
- 80
- Run by
- Jacobio Pharmaceuticals Co., Ltd.
See details and how to joinNCT07640295 - Phase 2Taking peopleAn Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 60
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT06938282 - Early phase 1Taking peopleA IIT Study of 177Lu-DOTA-SNA040
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 12
- Run by
- SmartNuclide Biopharma
See details and how to joinNCT07595237 - Phase 1/2Not yet taking people in ChinaJDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 10
- Run by
- West China Hospital
See details and how to joinNCT07175389 - Phase 3Taking peoplePhase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 320
- Run by
- Genfleet Therapeutics (Shanghai) Inc.
See details and how to joinNCT07262567 - Phase 1/2Taking peoplePhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Where
- Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou
- Age
- 18 years and over
- People
- 240
- Run by
- Allist Pharmaceuticals, Inc.
See details and how to joinNCT05288205 - Phase 1Taking peopleA Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- Where
- Beijing, Changsha, Chongqing, Heilongjiang, Shandong, Shanghai, Wuhan, Zhejiang, Zhengzhou
- Age
- 18 years and over
- People
- 572 worldwide
- Run by
- ArriVent BioPharma, Inc.
See details and how to joinNCT07066657 - No phaseNot yet taking people in ChinaRisk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs
- Where
- Jinan
- Age
- 18 years to 85 years
- People
- 600
- Run by
- Qilu Hospital of Shandong University
See details and how to joinNCT07136701 - Phase 1Taking peopleYMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies
- Where
- Chengdu
- Age
- 18 years to 75 years
- People
- 9
- Run by
- West China Hospital
See details and how to joinNCT07763301 - Phase 2Taking peopleA Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 30
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07438106 - Early phase 1Taking peopleA Study of GC203 TIL in PDCA (RJ)
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 10
- Run by
- Shanghai Juncell Therapeutics
See details and how to joinNCT06828328 - Phase 2Not yet taking people in ChinaSafety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 20
- Run by
- Ruijin Hospital
See details and how to joinNCT07745790 - Phase 1Taking peopleAMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Where
- Beijing, Chongqing, Jinan
- Age
- 18 years and over
- People
- 434 worldwide
- Run by
- Amgen
See details and how to joinNCT07094113 - Phase 2Taking peopleA Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
- Where
- Beijing, Changchun, Chengdu, Dalian, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shanghai, Shenyang, Wuhan, Zhengzhou
- Age
- 18 years and over
- People
- 105 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07255404 - Phase 1Taking peopleStudy of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
- Where
- Tianjin
- Age
- 18 years and over
- People
- 493
- Run by
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
See details and how to joinNCT07589205 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Beijing, Shanghai
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 1Taking peopleA Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Where
- Guangzhou, Jinan, Shanghai
- Age
- 18 years and over
- People
- 914 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840 · EU 2023-505858-18-00 - Phase 3Taking peopleAuricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound
- Where
- Hangzhou
- Age
- 18 years to 85 years
- People
- 74
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07716228 - Early phase 1Taking peopleA Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 10
- Run by
- Huashan Hospital
See details and how to joinNCT07707531 - Phase 1Not yet taking people in ChinaHSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
- Where
- Shanghai
- Age
- 18 years and over
- People
- 258
- Run by
- Haisco Pharmaceutical Group Co., Ltd.
See details and how to joinNCT07699757 - Phase 3Taking peopleSurufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 106
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07436741 - Phase 1/2Taking peopleIBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 56
- Run by
- Zhejiang Cancer Hospital
See details and how to joinNCT07692750